CF Industries Holdings, Inc. vs Revvity Inc — how do they compare? CF Industries Holdings, Inc. trades at $115.39 (market cap $17.83B), while Revvity Inc trades at $115.25 (market cap $12.91B). The key difference: CF Industries Holdings, Inc. is the larger of the two by market cap, and CF Industries Holdings, Inc. pays the higher dividend (2.04%). Which is the better fit depends on your goals.
| CF | RVTY | |
|---|---|---|
Market Cap | $17.83B | $12.91B |
Sector | Basic Materials | Technology |
52-Week High | $137.55 | $117.75 |
52-Week Low | $76.08 | $82.26 |
Enterprise Value | $18.96B | $15.23B |
Dividend Yield | 2.04% | 0.24% |
Signals from Pluang's Aura AI — not financial advice
CF Industries Holdings (CF) trades at $121.52, up 6.27% in the past 24 hours, with a bullish technical signal from moving averages. The stock exhibits strong profitability with a net income margin of 27.12% and ROE of 39.19%. Recent Q2 2026 earnings of $4.73 per share missed estimates, but the company reported strong nitrogen pricing and raised its mid-cycle earnings outlook. Analyst consensus is a Buy with a $119.60 price target, slightly below the current price.
The outlook for CF is supported by tight global nitrogen supply-demand dynamics and strong operating performance, with projected 2026 revenue of $7.7B and net income of $2.1B. Risks include volume volatility, as seen in the Q2 miss, and exposure to commodity price swings. The stock presents a value opportunity with a low P/E of 8.74, but investors should monitor execution on volume recovery and cost management.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Trailing returns across standard periods
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →